Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
Intended for Healthcare Professionals
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
  • Subscribe BJGP on YouTube
British Journal of General Practice
Intended for Healthcare Professionals

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
Editorials

Hormonal contraception and suicide: a new dimension of risk

Lloyd D Hughes and Olwkayode Majekodunmi
British Journal of General Practice 2018; 68 (676): 512-513. DOI: https://doi.org/10.3399/bjgp18X699473
Lloyd D Hughes
General Adult Psychiatry Services, Stratheden Hospital, Cupar, Fife, UK.
Roles: GP Registrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olwkayode Majekodunmi
General Adult Psychiatry Services, Stratheden Hospital, Cupar, Fife, UK.
Roles: Consultant Psychiatrist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info
  • eLetters
  • PDF
Loading

GENDER AND MENTAL HEALTH

Women have a higher lifetime prevalence of mood or anxiety disorders than men,1,2 with sex and gender differences within psychiatric diagnoses and course of psychiatric illness more broadly well documented.3

In a recent review, Christine Kuehner identified a wide range of potential reasons for this sex divide.4 These included; the influence of sex hormones; women’s blunted hypothalamic–pituitary–adrenal axis response to stress; girls’ and women’s lower self-esteem and higher tendency for body shame and rumination; higher rates of interpersonal stressors; and experience of violence, and childhood sexual abuse.4 With such a broad range of potential implicating risk factors, there has been a drive for research to focus and analyse some of these areas.

HORMONAL CONTRACEPTION & SUICIDE

In a recent study in the American Journal of Psychiatry, Skovlund and colleagues provide an elegant and eye-opening report of their finding that hormonal contraception use doubles the risk of suicide attempt, and triples the risk of suicide.5

The study utilised a nationwide registry in Denmark to identify 475 802 women, with a mean follow-up of 8.3 years: 54% of the cohort used hormonal contraception at some point during the study period. Patients with a known history of psychiatric diagnoses, including previous suicide attempts or prescription of antidepressants, were excluded from analysis, and patients were censored temporarily during pregnancy and 6 months after delivery to reduce the influence of postpartum depression. The outcome measure was death by suicide, and a diagnosis and/or contact with healthcare provider with ‘suicide attempt’ coding.

The authors reported that adolescent women are more sensitive than older women to the influence of hormonal contraception on first suicide attempt. In terms of dose–response effects, the risk of suicidal behaviour tended to be higher in women who received 50 μg compared to those who received 20–40 μg of ethinyl estradiol, and higher in those who used progesterone-only contraception. Non-oral hormonal contraception conferred the highest risk.

The association between hormonal contraception and primary outcomes peaked at 2 months, but continued even after the cessation of hormonal contraception for some years.

The strengths of this study are similar to other large-scale registry-based analyses: a large and representative sample; a long prospective follow-up; and careful methodology. Indeed, alongside censoring pregnancy, the authors differentiated between current and past use of hormonal contraception and reported effects by type of contraception. The study was able to clearly demonstrate that hormonal contraception preceded suicidal behaviour.

Limitations included a lack of information with regards to the risk factors that may well be influential in the relationship between hormonal contraception and suicidal behaviour. These include important social factors, such as relationship break-down/status, exposure to domestic abuse, and strong family history of mental health diagnoses. Being able to combine such data would be of particular relevance for primary care, where decisions about contraception are often made with information about the patients broader context more likely to be known than secondary care. The selection of comparison groups could have been associated with bias. With a younger age group hormonal versus non-hormonal forms of contraception may have been more valid. It could be postulated that earlier sexual encounter and risky sexual behaviour could be associated with suicidal behaviour. Finally, in the UK patients can be diagnosed with postnatal depression up until 12 months after delivery rather than the 6 months used as a censor in this study.

A PLAUSIBLE RELATIONSHIP BETWEEN HORMONES AND SUICIDE

The relationship between hormonal contraception exposure and suicidal behaviour is plausible for several reasons.6 Previous work by Skovlund and colleagues7 reported an association between hormonal contraception and depression (a 70% higher risk of depression among users of hormonal contraception compared to non-users), and indeed in clinical practice mood symptoms are a common reason for patients to cease hormonal contraception or change to a different preparation. A double-blind, placebo-controlled trial looking at the sex hormone manipulation with goserelin (a gonadotropin-releasing hormone agonist) found that women receiving goserelin experienced subclinical depressive symptoms, and these symptoms were positively associated with an overall decrease in estradiol levels.8 The study also reported cerebral changes on positron emission tomography.8 There have been other neuroimaging studies which have shown alterations in brain structure and functioning associated with contraceptive use.6,9 However, a recent randomised study which assigned women with a history of depression in the follicular phase of the menstrual cycle, to receive 30 μg of ethinyl estradiol/0.15 mg levonorgestrel or placebo, did not find an association between alterations in brain functioning and depressive symptoms.10

PLACING RESEARCH IN CONTEXT

How should this study begin to influence clinical practice? The first thing to stress is that women on hormonal contraception, of all forms, should not stop using them. The improvement in the provision of sexual health and contraceptive options for women has been a key development over the past 20 years, and it is important not to use this data to lead to hesitancy in prescribing contraception to patients. Indeed, the most recent MBRRACE-UK (Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK) report looking at maternal deaths between 2013 and 2015 found that maternal suicide is the third largest cause of direct maternal deaths occurring during or within 42 days of the end of pregnancy.11 Furthermore, suicide remains the leading cause of direct deaths occurring during pregnancy, or up to a year after pregnancy.11

The relationship between unintended pregnancy and abortion on mental health outcomes is not clear. There had been concerns following a review that reported higher risk of mental health conditions after an abortion.12 However, numerous flaws and methodological issues were reported and discussed at length13,14 and there is no clear consensus on this issue presently, with longitudinal research on this issue planned.

However, it can be now argued that we should be counselling patients regarding mood side effects with hormonal contraception, with the caveat that the study effect for the individual will be small. This can provide the basis for a patient–healthcare professional discussion, with patients encouraged to highlight concerns in their mood fluctuations after starting treatment to their clinician.

Further work is needed to try and further decipher the relationship between hormones and mental health, and how known social risk factors for affective disorders may interact with hormonal fluctuations and hormonal treatment. Based on the results of the study by Skovlund and colleagues, it would be prudent for GPs to consider mental health risk factors when starting and reviewing hormonal contraception in the management and treatment of female patients in the community.

Notes

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors have declared no competing interests.

  • © British Journal of General Practice 2018

REFERENCES

  1. 1.↵
    1. Riecher-Rössler A
    (2010) Prospects for the classification of mental disorders in women. Eur Psychiatry 25(4):189–196.
  2. 2.↵
    1. Seedat S,
    2. Scott KM,
    3. Angermeyer MC,
    4. et al.
    (2009) Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry 66(7):785–795.
  3. 3.↵
    1. Reicher-Rössler A
    (2016) Sex and gender differences in mental disorders. Lancet Psychiatry 4(1):8–9.
  4. 4.↵
    1. Kuehner C
    (2017) Why is depression more common among women than among men? Lancet Psychiatry 4(2):146–158.
  5. 5.↵
    1. Skovlund CW,
    2. Mørch LS,
    3. Kessing LV,
    4. et al.
    (2018) Association of hormonal contraception with suicide attempts and suicides. Am J Psychiatry 175(4):336–342.
  6. 6.↵
    1. Brent D
    (2018) Contraceptive conundrum: use of hormonal contraceptives is associated with an increased risk of suicide attempt and suicide. Am J Psychiatry 175(4):300–302.
  7. 7.↵
    1. Skovlund CW,
    2. Mørch LS,
    3. Kessing LV,
    4. Lidegaard Ø
    (2016) Association of hormonal contraception with depression. JAMA Psychiatry 73(11):1154–1162.
  8. 8.↵
    1. Frokjaer VG,
    2. Pinborg A,
    3. Holst KK,
    4. et al.
    (2015) Role of serotonin transporter changes in depressive responses to sex-steroid hormone manipulation: a positron emission tomography study. Biol Psychiatry 78(8):534–543.
  9. 9.↵
    1. Petersen N,
    2. Touroutoglou A,
    3. Andreano JM,
    4. et al.
    (2015) Oral contraceptive pill is associated with localised decreases in cortical thickness. Hum Brain Mapp 36(7):2644–2654.
  10. 10.↵
    1. Engman J,
    2. Sundström Poromaa I,
    3. Moby L,
    4. et al.
    (2018) Hormonal cycle and contraceptive effects of amygdala and salience resting-state networks in women with previous affective side effects on the pill. Neuropsychopharmacology 43(3):555–563.
  11. 11.↵
    1. Knight M,
    2. Nair M,
    3. Tuffnell D,
    4. et al.
    (2017) Saving lives, improving mothers’ care: lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013–15, https://www.npeu.ox.ac.uk/downloads/files/mbrrace-uk/reports/MBRRACE-UK%20Maternal%20Report%202017%20-%20Web.pdf (accessed 27 Sep 2018).
  12. 12.↵
    1. Coleman PK
    (2011) Abortion and mental health: quantitative synthesis and analysis of research published 1995–2009. Br J Psychiatry 199(3):180–186.
  13. 13.↵
    1. Kendall T,
    2. Bird V,
    3. Cantwell R,
    4. Taylor C
    (2012) To meta-analyse or not to meta-analyse: abortion, birth and mental health. Br J Psychiatry 200(1):12–14.
  14. 14.↵
    1. Steinberg JR,
    2. Trussell J,
    3. Hall KS,
    4. Guthrie K
    (2012) Fatal flaws in a recent meta-analysis on abortion and mental health. Contraception 86(5):430–437.
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 68 (676)
British Journal of General Practice
Vol. 68, Issue 676
November 2018
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Or,
sign in or create an account with your email address
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hormonal contraception and suicide: a new dimension of risk
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hormonal contraception and suicide: a new dimension of risk
Lloyd D Hughes, Olwkayode Majekodunmi
British Journal of General Practice 2018; 68 (676): 512-513. DOI: 10.3399/bjgp18X699473

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Hormonal contraception and suicide: a new dimension of risk
Lloyd D Hughes, Olwkayode Majekodunmi
British Journal of General Practice 2018; 68 (676): 512-513. DOI: 10.3399/bjgp18X699473
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • GENDER AND MENTAL HEALTH
    • HORMONAL CONTRACEPTION & SUICIDE
    • A PLAUSIBLE RELATIONSHIP BETWEEN HORMONES AND SUICIDE
    • PLACING RESEARCH IN CONTEXT
    • Notes
    • REFERENCES
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • Socioeconomic deprivation and post-stroke care in the community
  • Advocating for patients through laboratory tests: what do GPs’ use of blood tests for suspected cancer tell us?
  • Diagnosis of prostate cancer in primary care: navigating updated clinical guidance
Show more Editorials

Related Articles

Cited By...

Intended for Healthcare Professionals

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2023 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242